Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.

G, Breithardt; H, Baumgartner; SD, Berkowitz; AS, Hellkamp; JP, Piccini; SR, Stevens; Y, Lokhnygina; MR, Patel; JL, Halperin; DE, Singer; GJ, Hankey; W, Hacke; RC, Becker; CC, Nessel; KW, Mahaffey; KA, Fox; RM, Califf

doi:10.1093/eurheartj/ehu305

Public

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.

Shared by NobleBlocks on Aug 22, 2014 • 12:00 AM UTC

Authors:

Breithardt G

Baumgartner H

Berkowitz SD

Abstract

<h4>Aims</h4>We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) tria...

Subject

Anticoagulants

Heart diseases

Stenosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!